DexCom Net Receivables from 2010 to 2026
| DXCM Stock | USD 70.82 0.81 1.13% |
Net Receivables | First Reported 2006-06-30 | Previous Quarter 1.4 B | Current Value 1.1 B | Quarterly Volatility 355.5 M |
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom's main balance sheet or income statement drivers, such as Interest Expense of 12.2 M, Other Operating Expenses of 4.1 B or Operating Income of 724.5 M, as well as many indicators such as Price To Sales Ratio of 8.52, Dividend Yield of 0.0 or PTB Ratio of 10.1. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
DexCom | Net Receivables | Build AI portfolio with DexCom Stock |
Evaluating DexCom's Net Receivables across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into DexCom Inc's fundamental strength.
Latest DexCom's Net Receivables Growth Pattern
Below is the plot of the Net Receivables of DexCom Inc over the last few years. It is DexCom's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
DexCom Net Receivables Regression Statistics
| Arithmetic Mean | 416,401,882 | |
| Geometric Mean | 126,392,093 | |
| Coefficient Of Variation | 108.28 | |
| Mean Deviation | 381,211,626 | |
| Median | 226,700,000 | |
| Standard Deviation | 450,897,294 | |
| Sample Variance | 203308.4T | |
| Range | 1.2B | |
| R-Value | 0.94 | |
| Mean Square Error | 27077.9T | |
| R-Squared | 0.88 | |
| Slope | 83,530,627 | |
| Total Sum of Squares | 3252933.9T |
DexCom Net Receivables History
About DexCom Financial Statements
DexCom investors utilize fundamental indicators, such as Net Receivables, to predict how DexCom Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 1.2 B | 1.2 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of DexCom Correlation against competitors. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.099 | Earnings Share 1.8 | Revenue Per Share | Quarterly Revenue Growth 0.216 | Return On Assets |
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value - what DexCom's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.